The contribution of neuropilin‐1 in the stability of CD4+CD25+ regulatory T cells through the TGF‐β1/Smads signaling pathway in the presence of lipopolysaccharides. Issue 2 (10th November 2021)
- Record Type:
- Journal Article
- Title:
- The contribution of neuropilin‐1 in the stability of CD4+CD25+ regulatory T cells through the TGF‐β1/Smads signaling pathway in the presence of lipopolysaccharides. Issue 2 (10th November 2021)
- Main Title:
- The contribution of neuropilin‐1 in the stability of CD4+CD25+ regulatory T cells through the TGF‐β1/Smads signaling pathway in the presence of lipopolysaccharides
- Authors:
- Gao, Yulei
Zhang, Xiang
Wang, Ziyi
Qiu, Yuting
Liu, Yancun
Shou, Songtao
Chai, Yanfen - Abstract:
- Abstract: Introduction: This study investigates the synergistic effect of TGF‐β1 and Nrp‐1 on CD4 + CD25 + Tregs ' stabilization, and the associated pathways of signal transduction, in vitro models in the presence of LPS. Materials and Methods: Spleen CD4 + CD25 + Tregs cells of mice models in the presence of LPS, were transfected with an shRNA targeting Nrp‐1, Smad2, or Smad3, may or may not be treated with recombinant TGF‐β1. Followed by subsequent determination of cellular proliferation, rate of apoptosis, observation of the Foxp3, CTLA‐4, and TGF‐β1 m+ expression levels, foxp3‐TSDR methylation, secretion levels of the inhibitory cytokines IL‐10 and TGF‐β1, and Smad2/3 of CD4 + CD25 + Tregs expression. Results: A remarkable stimulation in CD4 + CD25 + Tregs ' stability is noted after administering recombinant TGF‐β1 in the presence of LPS, and promoted cellular viability, increased Foxp3, CTLA‐4, and TGF‐β1 m+ expression, and elevated secretion of IL‐10 and TGF‐β1. This also inhibited the apoptosis and methylation of foxp3‐ TSDR of CD4 + CD25 + Tregs . The shRNA transfection silenced Nrp‐1 and Smad3, but not Smad2, resulting in the suppression of the recombinant TGF‐β1‐mediated effects in the presence of LPS. Conclusions: According to the results, Nrp‐1 mediates TGF‐β1 to improve the stability of regulatory CD4 + CD25 + T cells and maybe a possible therapeutic target with the ability to improve the CD4 + CD25 + Tregs associated negative immunoregulation that is related toAbstract: Introduction: This study investigates the synergistic effect of TGF‐β1 and Nrp‐1 on CD4 + CD25 + Tregs ' stabilization, and the associated pathways of signal transduction, in vitro models in the presence of LPS. Materials and Methods: Spleen CD4 + CD25 + Tregs cells of mice models in the presence of LPS, were transfected with an shRNA targeting Nrp‐1, Smad2, or Smad3, may or may not be treated with recombinant TGF‐β1. Followed by subsequent determination of cellular proliferation, rate of apoptosis, observation of the Foxp3, CTLA‐4, and TGF‐β1 m+ expression levels, foxp3‐TSDR methylation, secretion levels of the inhibitory cytokines IL‐10 and TGF‐β1, and Smad2/3 of CD4 + CD25 + Tregs expression. Results: A remarkable stimulation in CD4 + CD25 + Tregs ' stability is noted after administering recombinant TGF‐β1 in the presence of LPS, and promoted cellular viability, increased Foxp3, CTLA‐4, and TGF‐β1 m+ expression, and elevated secretion of IL‐10 and TGF‐β1. This also inhibited the apoptosis and methylation of foxp3‐ TSDR of CD4 + CD25 + Tregs . The shRNA transfection silenced Nrp‐1 and Smad3, but not Smad2, resulting in the suppression of the recombinant TGF‐β1‐mediated effects in the presence of LPS. Conclusions: According to the results, Nrp‐1 mediates TGF‐β1 to improve the stability of regulatory CD4 + CD25 + T cells and maybe a possible therapeutic target with the ability to improve the CD4 + CD25 + Tregs associated negative immunoregulation that is related to the TGF‐β1/Smads cell signaling during sepsis. Abstract : Our results suggest that Nrp‐1 is beneficial for TGF‐β1 to enhance the stability of CD4 + CD25 + Tregs, and may represent a novel therapeutic target with the potential to improve the CD4 + CD25 + Tregs ‐related primary negative immunoregulation associated with the TGF‐β1/Smads signaling pathway in sepsis. … (more)
- Is Part Of:
- Immunity, inflammation and disease. Volume 10:Issue 2(2022)
- Journal:
- Immunity, inflammation and disease
- Issue:
- Volume 10:Issue 2(2022)
- Issue Display:
- Volume 10, Issue 2 (2022)
- Year:
- 2022
- Volume:
- 10
- Issue:
- 2
- Issue Sort Value:
- 2022-0010-0002-0000
- Page Start:
- 143
- Page End:
- 154
- Publication Date:
- 2021-11-10
- Subjects:
- lipopolysaccharides -- negative immunoregulation -- neuropilin‐1 -- regulatory T cells -- Sepsis -- transforming growth factor‐β1
Immunology -- Periodicals
Immunity -- Periodicals
Inflammation -- Periodicals
616.079 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2050-4527 ↗
http://onlinelibrary.wiley.com/ ↗
http://www.wileyopenaccess.com/view/journals.html ↗ - DOI:
- 10.1002/iid3.551 ↗
- Languages:
- English
- ISSNs:
- 2050-4527
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20644.xml